Tarsicio Gacheru
Psychiatric/Mental Health · Columbus, OHNPI 1164854295
Payments from drug & device makers
Across 1,097 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Teva Pharmaceuticals USA, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Axsome Therapeutics, Inc.$1K
- Sunovion Pharmaceuticals Inc.$1K
- plus $6K from 15 others
What the payments were for
- Food & beverage$17,52699%
- Education$1471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 242 | $3,171 |
| Teva Pharmaceuticals USA, Inc. | 173 | $2,514 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 127 | $1,862 |
| Otsuka America Pharmaceutical, Inc. | 107 | $1,787 |
| Axsome Therapeutics, Inc. | 63 | $1,491 |
| Sunovion Pharmaceuticals Inc. | 86 | $1,343 |
| Lundbeck LLC | 68 | $1,055 |
| E.r. Squibb & Sons, L.L.C. | 46 | $886 |
| Vanda Pharmaceuticals Inc. | 28 | $723 |
| Neurocrine Biosciences, Inc. | 33 | $684 |
| Alkermes, Inc. | 33 | $538 |
| Indivior Inc. | 30 | $522 |
| Johnson & Johnson | 24 | $450 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $246 |
| Almatica Pharma LLC | 7 | $128 |
| Neos Therapeutics, LP | 6 | $107 |
| Avanir Pharmaceuticals, Inc. | 4 | $50 |
| Biogen | 2 | $44 |
| Noven Therapeutics, LLC | 3 | $40 |
| Luye Pharma (USA) Ltd. | 1 | $18 |
| Tris Pharma Inc | 1 | $15 |
How this compares
$17,673 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 130 | $410,477 |
| IngrezzaValbenazine Tosylate | 46 | $362,660 |
| AustedoDeutetrabenazine | 58 | $347,648 |
| Austedo XrDeutetrabenazine | 43 | $304,207 |
| RexultiBrexpiprazole | 130 | $189,738 |
| VraylarCariprazine Hcl | 75 | $109,544 |
| UzedyRisperidone | 25 | $84,866 |
| PerserisRisperidone | 25 | $68,846 |
| AristadaAripiprazole Lauroxil | 23 | $68,071 |
| Abilify MaintenaAripiprazole | 20 | $58,886 |
| AuvelityDextromethorphan Hbr/Bupropion | 57 | $50,170 |
| Lurasidone Hcl | 158 | $42,977 |
| TrintellixVortioxetine Hydrobromide | 69 | $34,833 |
| CaplytaLumateperone Tosylate | 16 | $25,990 |
| VyvanseLisdexamfetamine Dimesylate | 35 | $14,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Uzedy | $2,514 | $736,722126 claims |
| Johnson & JohnsonInvega Sustenna | $450 | $410,477130 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $684 | $362,66046 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,787 | $248,624150 claims |
| AbbVieVraylar | $3,171 | $109,54475 claims |
| Indivior Inc.Perseris | $522 | $68,84625 claims |
| Alkermes, Inc.Aristada | $538 | $68,07123 claims |
| Axsome Therapeutics, Inc.Auvelity | $1,491 | $50,17057 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $246 | $49,078104 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,862 | $25,99016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Columbus
- Holly SchweitzerColumbus$78K
- David HuffmanColumbus$50K
- Alicja MatusiakColumbus$11K
- Summer LawsonColumbus$11K
- Gregory BlankenshipColumbus$10K
- Jennifer WilsonColumbus$10K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.